Literature DB >> 18378540

What to do with an abnormal PSA test.

Stacy Loeb1, William J Catalona.   

Abstract

For more than a decade, prostate-specific antigen (PSA) has been used for prostate cancer screening. Over the years, this screening has been continually refined, including investigation into the use of lower total PSA thresholds, PSA isoforms, and PSA kinetics. This review describes the evolution of prostate cancer screening and provides clinical insights into the informed use of PSA and its adjunctive measurements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378540     DOI: 10.1634/theoncologist.2007-0139

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

1.  Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer.

Authors:  Xingyan Liu; Zhiwei He; Cai-Hong Li; Guoliang Huang; Congcong Ding; Hong Liu
Journal:  Pathol Oncol Res       Date:  2011-06-18       Impact factor: 3.201

2.  Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.

Authors:  Darina Kachakova; Atanaska Mitkova; Elenko Popov; Ivan Popov; Alexandrina Vlahova; Tihomir Dikov; Svetlana Christova; Vanio Mitev; Chavdar Slavov; Radka Kaneva
Journal:  DNA Cell Biol       Date:  2014-12-18       Impact factor: 3.311

3.  Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples.

Authors:  Mark Stovsky; Lee Ponsky; Srinivas Vourganti; Peter Stuhldreher; Mike B Siroky; Victor Kipnis; Olga Fedotoff; Larissa Mikheeva; Boris Zaslavsky; Arnon Chait; J Stephen Jones
Journal:  Urology       Date:  2011-07-23       Impact factor: 2.649

4.  Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer.

Authors:  Celia Prior; Francisco Guillen-Grima; Jose E Robles; David Rosell; Jose M Fernandez-Montero; Xabier Agirre; Raúl Catena; Alfonso Calvo
Journal:  World J Urol       Date:  2010-07-15       Impact factor: 4.226

5.  CD147 expression indicates unfavourable prognosis in prostate cancer.

Authors:  Zhao-dong Han; Xue-cheng Bi; Wei-jun Qin; Hui-chan He; Qi-shan Dai; Jun Zou; Yong-kang Ye; Yu-xiang Liang; Guo-hua Zeng; Zhi-nan Chen; Wei-de Zhong
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

6.  Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Authors:  M Scott Lucia; Amy K Darke; Phyllis J Goodman; Francisco G La Rosa; Howard L Parnes; Leslie G Ford; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

7.  Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer.

Authors:  Dali Huang; George P Casale; Jun Tian; Subodh M Lele; Vladimir M Pisarev; Melanie A Simpson; George P Hemstreet
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

8.  Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.

Authors:  Udara Dharmasiri; Subramanian Balamurugan; André A Adams; Paul I Okagbare; Annie Obubuafo; Steven A Soper
Journal:  Electrophoresis       Date:  2009-09       Impact factor: 3.535

9.  Carbonic anhydrase I as a new plasma biomarker for prostate cancer.

Authors:  Michiko Takakura; Akira Yokomizo; Yoshinori Tanaka; Michimoto Kobayashi; Giman Jung; Miho Banno; Tomohiro Sakuma; Kenjiro Imada; Yoshinao Oda; Masahiro Kamita; Kazufumi Honda; Tesshi Yamada; Seiji Naito; Masaya Ono
Journal:  ISRN Oncol       Date:  2012-11-19

Review 10.  Extracellular vesicles in prostate cancer: new future clinical strategies?

Authors:  Ilaria Giusti; Vincenza Dolo
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.